CAR T-Cell Therapy: What It Is & How It Works - Cleveland Clinic
Feb 14, 2024 · What is CAR T-cell therapy? Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy for some types of blood cancer. It works by turning your T lymphocytes …
CAR T cell - Wikipedia
In biology, chimeric antigen receptors (CARs)—also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors —are receptor proteins that have been …
Understanding CAR-T cell therapy for cancer: Mayo Clinic expert ...
Mar 19, 2025 · Chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, is one type of immunotherapy. Sometimes likened to a “smart drug” or “living drug,” CAR-T cell therapy …
CAR T-cell Therapy and Its Side Effects - American Cancer Society
CAR T-cell therapy or CAR T therapy (short for chimeric antigen receptor T-cell therapy) is a type of cell-based gene therapy that alters the genes in a person’s T cells (a type of white blood …
CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI
Feb 26, 2025 · CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers CAR T-cell therapy involves genetically engineering a patient's own T cells (red) to attack cancer cells …
What is CAR T-cell therapy and how does it work? - Drugs.com
Jul 11, 2025 · CAR T-cell therapy is a personalized treatment that uses a patient's own immune cells to fight certain cancers and autoimmune diseases. By harnessing and reprogramming a …
CAR-T | Johns Hopkins Kimmel Cancer Center
What is CAR-T? CAR-T therapy is a type of immunotherapy that uses a person’s own immune cells, called T cells, and makes them stronger so they can identify and attack cancer cells.
CAR T-Cell Therapy | Fact Sheets | Yale Medicine
Car T-Cell Therapy is a form of immunotherapy that uses modified T-cells within a patient's body to kill cancer cells. Learn more about this treatment.
Results show long-lasting benefits of CAR T cell therapy for hard …
Severe cytokine release syndrome, a common side effect of CAR T cell therapy, occurred in 1% of patients, while severe neurological events occurred in 2% of patients.
Delayed toxicities after CAR T cell therapy for ... - Penn Medicine
1 day ago · Blood cancers Cancer CAR T cell therapy Immunotherapy Translational research Delayed toxicities after CAR T cell therapy for multiple myeloma are connected and potentially …